Biological characterization of laryngeal squamous-cell carcinoma

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2257-2267

  Tomasino, Rosa Maria ^a,c   Bazan, Viviana ^b   Daniele, Elio ^a   Nuara, Rosabianca ^a   Morello, Vincenza ^a   Tralongo, Vincenzo ^a   Leto, Gaetano ^a,b   Russo, Antonio ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NONE   (Italy)

Author keywords

Biological characterization; Diagnosis; Laryngeal squamous cell carcinoma

Indexed keywords

CYCLINE; CYSTEINE PROTEINASE; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL KINETICS; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; LYSOSOME; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 11; DNA, NEOPLASM; FLOW CYTOMETRY; GENES, P53; GENES, RAS; HUMANS; LARYNGEAL NEOPLASMS;

EID: 0029788677     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Batsakis JK: Tumours of head and neck: clinical and pathological considerations. Baltimore, William and Wilkins, 1974.
2. Field JK and Spandidos DA: Expression of oncogenes in human tumours with special reference to the head and neck region. J Oral Pathol 16: 97-107, 1987.
3. Sessions RB, Harrison LB and Hong WK: Tumours of the larynx and hypopharynx. In: Cancer principles and practic of oncology (De Vita V. jr, Hellman S and Rosenberg SA, eds). Philadelphia, JB Lippincott Company, 1993, pp 631-654.
4. Pera E, Moreno A and Galindo L: Prognostic factors in laryngeal carcinoma. A multifactorial study of 416 cases. Cancer 5A: 928-934, 1986.
5. Eiband JD, Elias EG, Suter CM, Gray WC and Didolkar MS: Prognostic factors in squamous-cell carcinoma of the larynx. Am J Surg 158: 314-317, 1989.
6. Pradier R, Gonzalez A, Matos E, Loria D, Adan R, Saco P and Califano L: Prognostic factors in laryngeal carcinoma. Experience in 296 male patients. Cancer 71: 1472-1476, 1993.
7. Tennvall J, Wennerberg J, Willen R, Ask A, Baldertorp B and Ferno M: T3N0 glottic carcinoma: DNA S-phase as a predictor of the outcome after radiotherapy. Acta Otolaryngol (Stockh) 113: 220-224, 1993.
8. Goldsmith MM, Cresson DS, Postma DS, Askin FB and Pillsbury HC: Significance of ploidy in laryngeal cancer. Am J Surg 152: 396-402, 1986.
9. Russo A, Bazan V, Gebbia N, Tumminello FM, Dardanoni G, Pizzolanti G, Ingria F, Restivo S, Tomasino RM and Leto G: Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer: relationship whith clinico-pathological parameters and prognostic significance. Cancer, in press, 1995.
10. Maurizi M, Scambia G, Bcnedetti Panici P, Ferrandina G, Almadori G, Paludetti G, De Vinccnzo R, Di Stefano MG, Brinchi D, Cadoni G and Mancuso S: EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance. Int J Cancer 52: 862-866, 1992.
11. Tomasino RM, Morello V, Bazan V, Nagar C, Tralongo V, Dardanoni G, Ingria F, Monteleone G, Restivo S, Nuara R, Daniele E and Russo A: P53 expression in stage III-IV squamous-cell carcinoma lof the larynx: an immunoistochemical study related to clinico-pathological, flow-cytometric DNA analysis and prognosis. Int J Oncol 5: 495-500, 1994.
12. Kiaris H and Spandidos DA: Analysis of H-ras, K-ras and N-ras genes for expression, mutation and amplification in laryngeal tumours. Int J Oncol 7: 75-80, 1995.
13. Munck-Wikland E, Edstrm S, Jungmark E and Auer G: Nuclear DNA content, proliferating-cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions. Int J Cancer 56: 95-99, 1994.
14. Fracchiolla NS, Pignataro L, Capaccio P, Trecca D, Boletini A, Ottaviani A, Polli E, Maiolo AT and Neri A: Multiple genetic lesions in laryngeal squamous-cell carcinomas. Cancer 75: 1292-1301, 1995.
15. Tomasino RM, Daniele E, Bazan V, Morello V, Tralongo V, Nuara R, Nagar C, Salvato M, Ingria F, Restivo S, Dardanoni G, Vecchione A and Russo A: The prognostic significance of cell kinetics in laryngeal squamous-cell carcinoma: clinico-pathological associations. Data submitted for publication.
16. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply and metabolic microenviroment of human tumours: a review. Cancer Res 49: 6449-6465, 1989.
17. Broders AC: Carcinoma grading and practical application. Arch Pathol 2: 376-381, 1926.
18. Roland NJ, Caslin AN, Nash J and Stell PM: Value of grading squamous-cell carcinoma of the head and neck. Head and Neck 14: 224-229, 1992.
19. Ensley JF, Crissman J, Kish J, Jacobs J, Weaver A, Kinzie J, Cummings and Al-Sarraf: The impact of conventional morphological analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin containing combination chemotherapy. Cancer 57: 711-717, 1986.
20. Klijanienko J, El-Naggar AK, De Braud F, Rodriguez-Peralto JL, Rodriguez R, Itzhaki M, Russo A, Janol F, Luboinski B and Cviekovic E: Tumour vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous-cell carcinomas. Cancer 75: 1649-1656, 1995.
21. Kashima HK: The characteristics of laryngeal cancer correlating with with cervical lymph node metastasis. In: Workshops from the Centennial Conference on Laryngeal Cancer. Toronto, Canada. Appleton. Century Crofts, 1974, pp 855-864.
22. Shan J and Randall H: Epidermoid carcinoma of supraglottic larynx. Am J Surg 128: 494-499, 1974.
23. Sala O and Ferlito A: Morphological observations of immunology of laryngeal cancer. Acta Otolaryngol (Stockh) 81: 353-363, 1976.
24. Mc Gavran MH, Haver WC and Ogura JH: The incidence of cervical lymph node metastases from epidermoid carcinoma of the larynx and their relationship to certain characteristics of the primary tumour. Cancer 14: 55-65, 1961.
25. Jaekohson PA, Eneroth CM, Killander D, Moberger G and Martensen B: Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys Biol 12: 1-8. 1973.
26. Truelson JM, Fisher SG, Beals TE, McClatchey KD, Wolf GT and the Cooperative Laryngeal Cancer Study Group: DNA content and histological growth pattern correlate with advanced squamous-cell carcinoma of the larynx. Cancer 70: 56-72, 1992.
27. Begg AC, Hofland I, Moonen L, Bartelink H, Schraub S, Bontemps P, Le Fur R, van Den Bogaert W, Caspers R, van Glabbeke M and Horiot JC: The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumours: an interim report, Int J Radiat Oncol Biol Phys 19: 1449-1453, 1990.
28. Quinn CM and Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 160: 93-102, 1990.
29. Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P and Bonadonna G: Prognostic implication of labelling index versusoestrogen receptors and tumour size in node-negative breast cancer. Breast Cancer Res Treat 7: 161-167, 1986.
30. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F and Adnet JJ: Improvement in the staining and in the visualization of the argyrophilic proteins of the nuclear organizer region at the optical level. Histochem J 18: 5-14, 1986.
31. Haapasalo H, Pesonen E and Collan Y: Volume corrected mitotic index (M/V index). The standard of mitotic activity in neoplasia. Path Res Pract 185: 551-554, 1989.
32. Fairman MP: DNA polymerase-delta/PCNA and interactions. J cell Sci 94: 1-4, 1990.
33. Morris GF and Mathews MB: Regulation of proliferating cell nuclear antigen during the cell cycle. J Cell Biol 264: 13856-13864, 1989.
34. Beserga R: Growth regulation of the PCNA gene. J Cell Sci 98: 433-436, 1991.
35. Mercer WE, Shields MT, Ling D, Appella E and Ulrich SJ: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating cell nuclear antigen expression. Proc Natl Acad Sci USA 88: 1958-1962, 1991.
36. Shivji MKK, Kenny MK and Wood RD: Proliferating cell nuclear antigen (PCNA) is required for DNA excision repair. Cell 69: 1-20. 1992.
37. Battersby S and Andersson TJ: Correlation of proliferative activity in breast tissue using PCNA/cyclin. Hum Pathol 21: 781, 1990.
38. Siitonen SM, Isola JJ, Rantala IS and Helin HI: Intratumoural variation in cell proliferation in breast carcinoma as determined by anti-PCNA monoclonal antibody and automated image analysis. A J Clin Pathol 99: 226-231, 1993.
39. Leong As-Y, Milios J and Tang SK: Is immunolocalization of proliferating cell nuclear antigen (PCNA) in paraffin sections a valid index of cell proliferation? Appl Immunohistochem 12: 127-135, 1993.
40. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK and Hittelman WN: Sequential increases in proliferating cell nuclear antigen expression in head and neck tnmourigenesis: a potential biomarker. J Natl Cancer Inst 85: 971-978, 1993.
41. Kruth HS: Flow cytometry: rapid biochemical analysis of single cells. Ann Biochem 125: 225-242, 1982.
42. Silvestrini R, Daidone MG, Del Bino G, Mastore M, Luisi A, Di Fronzo G and Boracchi P: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 4: 213-219, 1993.
43. Russo A, Bazan V, Morello V, Tralongo V, Nagar C, Nuara R, Dardanoni G, Bazan P and Tomasino RM: Vimentin expression, proliferating cell nuclear antigen and flow cytometric factor. Prognostic role in breast cancer. Analyt Ouant Cytol Histol 16: 365-374, 1994.
44. Russo A, Bazan V, Playa S, Cajozzo M and Bazan P: Flow cytometric DNA analysis of hepatic tumours on ultrasound-guided fine-needle aspirates. J Surg Oncol 51: 26-32, 1992.
45. Marrazzo A, Russo A, Bazan V, Taormina P, Lupo F and Bazan P: Immunocytochemical determination of oestrogen and progesteron receptors and flow cytometric DNA analysis of breast cancer on fine needle aspirates. Anticancer Res 134: 2435-2440, 1993.
46. Merkel DE and McGuire WL: Ploidy: proliferative activity and prognosis: DNA flow cytometry of solid tumours. Cancer 65: 1194-1205, 1990.
47. Ross DW: Clinical usefulness of DNA-ploidy and cell cycle studies. Arch Pathol Lab Med 117: 1077, 1993.
48. Russo A, Bazan V, Playa S, Leonardi P and Bazan P: Patterns of DNA-ploidy in operable colorectal carcinoma: a prospective study of 100 cases. J Surg Oncol 48: 4-10, 1991.
49. Russo A, Bazan V, Campanella R, Dardanoni G, Carreca I, Cucciarre S, Vecchione A and Pavone-Macaluso M: Flow cytometric DNA analysis in the prediction of intravesical recurrence from human bladder cancer. Int J Oncol 5: 633-638, 1994.
50. De Vita R, Forte D, Maggi F, Eleuteri P and Di Silverio F: Cellular DNA content and proliferative activity evaluated by flow cytometry versus histopathological and staging classifications in human bladder tumours. Eur Urol 19: 65-73. 1991.
51. Ruà S, Comino A, Fruttero A, Cera G, Semeria C, Lanzillotta L and Boffetta P: Relationship between histological features, DNA flow cytometry, and clinical behaviour of squamous-cell carcinomas of the larynx. Cancer 67: 141-149, 1991.
52. El-Naggar A, Lopez-Varela V, Luna MA, Weber R and Batsakis: Intratumoural DNA content heterogeneity in laryngeal squamous-cell carcinoma. Arch Otolaryngol Head Neck Surg 118: 169-173, 1992.
53. Barrett AJ and Kirschke H: Cathepsin B, cathepsin H and cathepsin L. Meth Enzymol 80: 535-561, 1981.
54. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Cancer Met Rev 10: 145-155, 1992.
55. Kirschke H, Langner J, Rieman S, Wiederanders B, Ansorge S and Bohley P: Lysosomal cysteine proteinases. In: Protein Degradation in Health and Disease. Ciba Foundation Symposium 75, Amsterdam. Excepta Medica, 1980, pp-15-35.
56. Baici A and Strauli P: Release of proteinases by culture of human cell lines derived from squamous carcinomas of the tongue and larynx. Exp Cell Biol 53: 219-131, 1985.
57. Marsigliante S, Biscozzo L, Resta L, Leo G, Mottaghi A, Maiorano E, Colucci G, and Storelli C: Immunohistochemical and immunoradiometric evaluation of total cathepsin D in human larynx. Oral Oncol Eur J Cancer, 30B: 51-55, 1994.
58. Zeillinger R, Swoboda H, Machacek D, Nekahm D, Sliutz G, Knogler W, Speiser P, Swoboda E and Kubista E: Expression of cathepsin D in head and Neck cancer. Eur J Cancer 28A: 1413-1415, 1992.
59. Leto G, Tumminello FM, Russo A, Pizzolanti G, Bazan V and Gebbia N: Cathepsin D activity levels in colorectal cancer: correlation with cathepsin B and L and other biological and clinical parameters. Int J Oncol 5: 509-515, 1994.
60. Campanella R, Russo A, Plaja S, Bazan V, Pavone C, Corselli G and Pavone-Macaluso M: Study of cellular DNA content by flow cytometry in primary bladder carcinomas. Significance of monoclonal and multiclonal varieties of DNA aneuploidy. Eur Urol 21: 58-63, 1992.
61. Kane SE and Gottesman MM: The role of cathepsin L in malignant transformation. Semin Cancer Biol 1: 127-136, 1990.
62. Chauhan SS, Goldstein LJ and Gottesmann MM: Expression of cathepsin L in human tumours. Cancer Res 51: 1478-1481, 1991.
63. Sloane BF: Cathepsin B and cystatin: evidence for a role in cancer progression. Semin Cancer Biol 1. 137-152, 1990.
64. Leto G, Pizzolanti G, Tumminello FM and Gebbia N: Effect of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumours. In Vivo 8: 231-236, 1994.
65. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M and Welsh D: The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumourigenesis. Br J Cancer 69: 409-416, 1994.
66. William ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E and Levine PA: Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 119: 1238-1243, 1993.
67. Tomasino RM, Morello V, Tralongo V, Nagar C, Nuara R, Daniele E, Curti-Giardina M and Orestano F: P53 expression in human renal cell carcinoma. An immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 86: 2273, 1994.
68. Albanese I, Alberti M, Bazan V, Russo A, Baiamonte S, Migli'avacca M, Bazan P and La Farina M: Structural analysis of c-myc in human sporadic colorectal carcinomas. Anticancer Res 14: 1103-1106, 1994.
69. Barbacid M: Ras genes. Ann Rev Bichem 56: 776-827, 1987.
70. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
71. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De Vincenzo R and Mancuso S: Significance of epidermal-growth-factor receptor in advanced ovarian cancer. J Clin Oncol 10: 529-535, 1992.
72. Anwar K, Nakakuki K, Naiki H and Inuzuki M: Ras gene mutations and HPV infection are common in human laryngeal carcinoma. Int J Cancer 53: 22-28, 1993.
73. Alitalo K, Koshkinem P, Makela TP, Saksela K, Sistonen L and Winqvist R: Myc oncogenes: activation and amplification. Biochem Biophys Acta 907: 1-32, 1987.
74. Lachman HM and Skoultchi AL: Expression of c-myc changes ;during differentiation of mouse erythroleukaemia cells. Nature 310: 592-594, 1984.
75. Hermeking H and Eick D: Mediation of C-myc-induced apoptosis by p53. Science 265: 2091-2093, 1994.
76. Escot C, Theillet C. Lidereau R, Spyratos F, Champeme MH, Gest J and Callahan R: Genetic alterations of the c-myc protooncogene (myc) in human primary breast carcinomas. Proc Natl Acad Sci USA 83: 4834-4838, 1986.
77. Saranath D, Chang SE, Bhoite LT, Panehal RG, Kerr IB, Metha AR, Johnson NW and Deo MG: High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing-tobacco-related human oral carcinoma in India. Br J Cancer 63: 573-578, 1991.
78. Leonard JH. Kearsley JH. Chenevix-Trench G and Hayward NK: Analysis of gene amplification in head and neck squamous-cell carcinomas. Int J Cancer 48: 511-515, 1991.
79. Jares P, Fernandez PE, Campo E, Nadal A, Boch F, Aiza G, Nayach I, Traserra J and Cardesa A: PRAD-1/Cyclin D1 gene amplification correlates with messenger RNA overexpression and tumour progression in human laryngeal carcinomas. Cancer Research 54: 4813-4817, 1994.
80. Hind P, Dowdy SF, Eaton EN, Arnold A and Weinberg RA: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci Usa 91: 709-713, 1994.
81. Jiang W, Kahn SM, Tomita N, Zhang Y, Lu S and Weir Amplification and expression of human cyclin D in oesophageal cancer. Cancer Res 52: 2980-2983, 1992.
82. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM and Arnold A: A novel cyclin encoded by BCL1-linked candidate oncogene. Nature (Lond.) 350: 512-515, 1991.
83. Berenson JR, Yang J and Mickel RA: Frequent amplification of bcl-1 locus in head and neck carcinomas. Oncogene 4: 1111-1116. 1989.
84. Somers KD, Cartwright SL and Schlechter GL: Amplification of the int-2 gene in human head and neck squamous-cell carcinomas. Oncogene 5: 915-920, 1990.
85. Weber RS, Pathak S, Frankenthaler R, Gallick GE and Sacks PG: Effect of epidermal growth factor (EGF) on a newly established head and neck squamous-carcinoma cell line. Otolaryngol Head Neck Surg 99: 567-573, 1988.
86. Ozawa S, Ueda M, Ando N, Shimizu N and Abe O: Prognostic significance of epidermal-growth-factors. Cancer 63: 2169-2173, 1989.
87. Sainsbury JRC, Farndon JR, Needham JK, Malcom AJ and Harris AL: Epidermal-growth-factor-receptor status as a predictor of early recurrence or of death from breast cancer. Lancet 1: 1398-1401, 1987.
88. Hishitoya J, Torijama M, Oguchi N, Kitamura K, Ohshima M, Asano K and Xamamoto T: Gene amplification and overexpression of EGF receptor in squamous-cell carcinomas of the head and neck. Brit J Cancer 59: 559-562, 1989.
89. Chang F, Syrjanen S, Kurvinen K and Syrjanen K: The p53 tumour suppressor gene as a common cellular target in human carcinogenesis. Amer J Gastroenterol 88: 174-186, 1993.
90. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B: Multifactorial analysis of p53 in human cancer: rewiew. Int J Cancer 27: 1-9, 1994.
91. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, Grandi E and Boiocchi M: High frequency of p53 alterations associated with protein over-expression in human squamous-cell carcinoma of the larynx, Oncogene 7: 1159-1166, 1992.
92. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, Romanelli M and Boiocchi M: P53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52: 178-182, 1992.
93. Anwar K, Nakakuki K, Imai H, Naikai H and Inuzuka M: Overexpression of p53 protein in human laryngeal carcinoma. Int J Cancer 53: 952-956, 1993.
94. Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H and Tsuchida N: The p53 tumour-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 52: 867-872, 1992.
95. Gorgoulolis V, Rassidakis G, Karameris A, Giatromanolaki A, Barbatis C and Kittas C: Expression of p53 protein in laryngeal squamous-cell carcinoma and dysplasia: possible correlation with human papilloma-virus infection and clinicopathological findings. Virch Arch 425: 481-489, 1994.
96. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK and Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumourigenesis. Cancer Res 54: 321-326, 1994.